|Bid||40.570 x 300|
|Ask||40.580 x 400|
|Day's Range||40.535 - 41.210|
|52 Week Range||38.140 - 50.650|
|PE Ratio (TTM)||9.86|
|Forward Dividend & Yield||1.64 (4.01%)|
|1y Target Est||N/A|
How far off is Sanofi (ENXTPA:SAN) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairly pricedRead More...
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
As discussed earlier, AstraZeneca surpassed Wall Street analyst estimates for earnings per share (or EPS) and revenues and reported EPS of $1.03 on revenues of ~$5.8 billion in 4Q17, a 3% increase in revenues as compared to revenues of 4Q16. AstraZeneca’s stock price has increased by nearly 14.9% over the last 12 months but decreased by ~2.6% in 2018 year-to-date. Wall Street analysts have a 12-month target price of $39.09 per share as compared to the last price of $33.78 per share as of March 8, 2018.
Esperion popped Monday after a study from Regeneron and Sanofi validated the long-term benefits of lowering LDL cholesterol.
Drugmakers tried just about every move under the sun to nurture sales of its products -- pharmacy coupons for patients, exclusive deals with insurers, even selling a medicine’s patent to a Native American ...
Regeneron CEO Leonard Schleifer says the biotech firm will lower the price of Praluent so long as insurers make it easier to claim a reimbursement.
Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.
Regeneron Pharmaceuticals Inc.'s plans to lower the price of its cholesterol-lowering medication Praluent sent shares of some of its rivals down in Monday premarket trade. Regeneron shares rose 1.6% premarket, ...
The makers of an expensive cholesterol-lowering drug plan to offer discounts of up to 69% in exchange for insurers and pharmacy-benefit managers expanding their coverage of the medicine to more patients....
A cholesterol drug made by Regeneron and Sanofi was shown to reduce the risk of cardiac events like heart attack and stroke, reports CNBC's Meg Tirrell with the latest results.